Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded

Roberto Cattaneo, Tanner Miest, Elena V. Shashkova, Michael A. Barry

Research output: Contribution to journalReview article

262 Scopus citations

Abstract

Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.

Original languageEnglish (US)
Pages (from-to)529-540
Number of pages12
JournalNature Reviews Microbiology
Volume6
Issue number7
DOIs
StatePublished - Jul 1 2008

ASJC Scopus subject areas

  • Microbiology
  • Immunology and Microbiology(all)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded'. Together they form a unique fingerprint.

  • Cite this